Method of reducing the undesirable gastrointestinal effects of prostaglandin synthetase inhibitors

摘要

There is disclosed concomitant systemic administration of prostaglandins of the PGB-type, for example, PGB2, and a prostaglandin synthetase inhibitor, for example, indomethacin, aspirin, or phenylbutazone, to mammals, including humans. Thereby the undesirable gastrointestinal effects of the synthetase inhibitor are reduced.